The purpose of this dose finding study is to compare two doses of MG01CI (1400 mg and 700 mg) to Placebo, in adult subjects with PI-ADHD. A crossover study design will allow evaluation of safety/tolerability and efficacy using validated computerized tests.~subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:~week 1:1400 mg, week 2:700 mg, week 3:placebo~week 1:700 mg,week 2: placebo,week 3:1400 mg~week 1: placebo, week2:1400 mg, week 3 700 mg~Overview of Study Visits~Screening Period:~Visit 1 - Screening/Baseline Visit (up to 7 days prior to dosing)~Treatment Period:~Visit 2 - Day 0 (Randomization Visit) Visit 3 - Day 7 ± 3 days Visit 4 - Day 14 ± 3 days Visit 5 - Day 21 ± 3 days~Follow-up period:~Visit 6 - Day 28 ± 3 days~Study duration for each subject will be up to 35 days .
study objectives are to compare the efficacy, safety and tolerability of two doses of MG01CI (1400 mg and 700 mg) to Placebo for the treatment of symptoms in adults diagnosed with PI-ADHD.~subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:~week 1:1400 mg, week 2:700 mg, week 3:placebo~week 1:700 mg,week 2: placebo,week 3:1400 mg~week 1: placebo, week2:1400 mg, week 3 700 mg~The study will consist of three periods: a screening period of up to one week, a 3-week double-blind treatment period, and a one-week safety follow-up period.